Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.35 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14175353 | 0.75 | CCNB2 (0.39) | CDK1CCNE2CCNE1CDK2 | |
| SCHEMBL5083570 | 0.73 | CDK1 (0.34) | CDK1CCNE2CCNA2CCNE1CDK2 | |
| SCHEMBL5083616 | 0.73 | CDK1 (0.34) | CDK1CCNA2CDK2CCNA1 | |
| SCHEMBL5082999 | 0.71 | HPRT1 (0.40) | CDK1CCNE2CCNE1CDK2 | |
| SCHEMBL5083699 | 0.70 | CDK1 (0.41) | CDK1CCNE2CCNA2CCNE1CDK2 | |
| SCHEMBL5083036 | 0.70 | CDK1 (0.34) | CDK1CCNE2CCNE1CDK2YTHDC1 | |
| SCHEMBL5083038 | 0.69 | CDK1 (0.41) | CDK1CCNE2CCNA2CCNE1CDK2 | |
| SCHEMBL5082996 | 0.69 | CDK1 (0.35) | CDK1CCNE2CCNE1CDK2 | |
| SCHEMBL5082981 | 0.68 | CCNE2 (0.34) | CDK1CCNE2CCNA2CCNE1CDK2 | |
| SCHEMBL5082380 | 0.68 | HPRT1 (0.38) | CDK1CCNE2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388002-B2 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | POLR2H, NSUN2, POLR2E | CDK1 704/4885CCNE2 240/4885CCNA2 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.